Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. junior Avg
|
|
New words:
assessing, Hedging, molecule, motion, seralutinib, Subtopic, traceable
Removed:
academic, accelerated, accomplish, advanced, advantage, American, assembled, attestation, auditor, billion, biotechnology, cancelable, cancer, chronic, collective, commence, complying, composition, consummation, deeply, deferred, delayed, designation, earliest, EMA, emerging, eosinophilic, European, exceeded, exemption, experienced, expertise, extended, filer, foundation, growth, histology, iii, initiate, irrevocably, iv, Jumpstart, lacked, large, leading, LEDA, limitation, multiple, nasal, opportunity, ordinary, orphan, pancreatic, pause, paused, pharmaceutical, private, promising, promulgated, rationale, recognition, rely, revised, scientific, Seed, skilled, Society, strong, tax, thereunder, TITAN, trade, transition, translational, unmet, viral, virtual, world
Filing tables
Filing exhibits
Related press release
GOSS similar filings
Filing view
External links
EXHIBIT 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
I, Bryan Giraudo, Chief Financial Officer of Gossamer Bio, Inc. (the “Company”), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
•the accompanying Quarterly Report on Form 10-Q of the Company for the quarter ended March 31, 2021 (the “Report”), as filed with the Securities and Exchange Commission, fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
•the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.
Date: May 6, 2021
| /s/ Bryan Giraudo | |||||
| Bryan Giraudo | |||||
| Chief Financial Officer | |||||
(Principal Financial and Accounting Officer) | |||||